Last Price | 0.02 | Max Price | 0.07 |
Min Price | 0.02 | 1 Year return | -97.01 |
Avg. Target | 0.00 | Expected Return | -100.00 % |
Sector | Health Care | Subsector | Biotechnology |
Sell | 0 | Rating | |
Hold | 0 | Concensus | |
Buy | 0 | ||
Annual report 2017 |
Contact info:Street: 37 Rue Auguste Piccard Postbox: 6041City: GosseliesCountry: BelgiumPhone: +32 (0)71 12.10.00Website: www.bonetherapeutics.com
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 0 | 141,925 | 0.00 % |
2020 | 1 | 170,231 | 0.00 % |
2021 | 1 | 252,886 | 0.00 % |
2022 | 0 | 238,500 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
The period from 2006 till the end of 2016 the international sector gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.
Over the past year the company' stock lost around 58 percent. Over the period from December 2011 till December 2016 the stock lost on average 0 percent. Bone Therapeutics's revenues between 2011 and 2015 were very volatile and moved between 3,05 million euros and 3,82 million euros.
Over the past 5 years the Belgian company paid out dividends.
At the end of 2015 Bone Therapeutics employed at around 67 people.
At the end of 2015 the biotech company's balance sheet equaled 50,38 million euros. Last year the total debt of the company was 22,24 million euros. This equals around 44,14 percent of the total balance sheet.
At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the biotech company equaled around 144,6 million euros. At the end of 2015 the Belgian company had around 7,42 million stocks listed on the exchanges.
All Bone Therapeutics's annual reports can be found here. More information about Bone Therapeutics can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
0
|
0
|
1
|
0
|
1
|
Costs |
14
|
13
|
13
|
15
|
10
|
13
|
Profit |
-14
|
-13
|
-13
|
-14
|
-10
|
-12
|
Margin of profit |
0.0
|
0.0
|
-31875.00
|
-1422.00
|
0.0
|
-1194.00
|
ROI |
-50.23
|
-85.07
|
-535.71
|
-316.70
|
-510.24
|
-358.56
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
28
|
15
|
2
|
4
|
2
|
3
|
Debt |
22
|
23
|
23
|
21
|
20
|
22
|
Total assets |
50
|
39
|
25
|
26
|
22
|
25
|
Solvency |
55.88
|
39.57
|
9.46
|
17.44
|
9.16
|
13.41
|
Cash |
34
|
20
|
8
|
8
|
9
|
15
|
Cashflow |
-12
|
-11
|
-11
|
-13
|
-10
|
-16
|
Employees |
101
|
94
|
94
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-0.53
|
-0.49
|
-0.48
|
-0.61
|
-0.51
|
-0.75
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
19.49
|
7.79
|
7.77
|
4.50
|
3.65
|
Eps |
-1.90
|
-1.86
|
-1.87
|
-1.10
|
-1.02
|
Price/earnings-ratio |
-10.26
|
-4.19
|
-4.16
|
-4.09
|
-0.02
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
2.23
|
0.35
|
0.54
|
0.19
|
0.20
|
Market to book |
0.11
|
0.04
|
0.07
|
0.04
|
10.10
|
Cashflow per stock |
-1.66
|
-1.61
|
-1.55
|
-0.97
|
-0.98
|
Stocks |
7
|
7
|
8
|
11
|
16
|
Market Cap |
133.50
|
53.36
|
64.57
|
48.02
|
0.33
|
Date
|
Price
|
---|---|
22 Mar 2024
|
0.02
|
18 Mar 2024
|
0.02
|
15 Mar 2024
|
0.02
|
12 Mar 2024
|
0.03
|
11 Mar 2024
|
0.03
|
09 Mar 2024
|
0.03
|
07 Mar 2024
|
0.03
|
01 Mar 2024
|
0.03
|
29 Feb 2024
|
0.03
|
27 Feb 2024
|
0.03
|
22 Feb 2024
|
0.03
|
21 Feb 2024
|
0.03
|
20 Feb 2024
|
0.03
|
15 Feb 2024
|
0.04
|
14 Feb 2024
|
0.04
|
13 Feb 2024
|
0.03
|
09 Feb 2024
|
0.04
|
08 Feb 2024
|
0.04
|
07 Feb 2024
|
0.04
|
06 Feb 2024
|
0.04
|
05 Feb 2024
|
0.04
|
01 Feb 2024
|
0.05
|
31 Jan 2024
|
0.05
|
30 Jan 2024
|
0.04
|
27 Jan 2024
|
0.04
|
25 Jan 2024
|
0.04
|
24 Jan 2024
|
0.04
|
23 Jan 2024
|
0.04
|
16 Jan 2024
|
0.06
|
11 Jan 2024
|
0.06
|